Special Considerations for Advanced Heart Failure Surgeries: Durable Left Ventricular Devices and Heart Transplantation.
Armaan Fazal AkbarAlice L ZhouAnnie WangAmy S N FengAlexandra A RizaldiJessica M RuckAhmet KılıçPublished in: Journal of cardiovascular development and disease (2024)
Heart transplantation and durable left ventricular assist devices (LVADs) represent two definitive therapies for end-stage heart failure in the modern era. Despite technological advances, both treatment modalities continue to experience unique risks that impact surgical and perioperative decision-making. Here, we review special populations and factors that impact risk in LVAD and heart transplant surgery and examine critical decisions in the management of these patients. As both heart transplantation and the use of durable LVADs as destination therapy continue to increase, these considerations will be of increasing relevance in managing advanced heart failure and improving outcomes.
Keyphrases
- heart failure
- left ventricular
- cardiac resynchronization therapy
- end stage renal disease
- decision making
- acute heart failure
- hypertrophic cardiomyopathy
- chronic kidney disease
- atrial fibrillation
- acute myocardial infarction
- ejection fraction
- minimally invasive
- left atrial
- prognostic factors
- mitral valve
- peritoneal dialysis
- patients undergoing
- cardiac surgery
- surgical site infection
- patient reported outcomes
- risk assessment
- cell therapy
- combination therapy
- mesenchymal stem cells
- skeletal muscle
- locally advanced
- insulin resistance
- adipose tissue
- patient reported
- genetic diversity